COCM
RVNC

Charter Oak Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Charter Oak Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500
Closed -$15K – 898
2021
Q2 		$15K Hold
500
– – ﹤0.01% 512
2021
Q1 		$14K Buy
+500
New +$13.8K ﹤0.01% 494

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Charter Oak Capital Management's RVNC Position: Q3 2021 in Review

Charter Oak Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2021, closing a stake of 500 shares — an estimated $15K sold.

Charter Oak Capital Management first reported a position in RVNC in Q1 2021 and held it in 2 quarters. The position peaked at $15K in Q2 2021. 158 funds tracked by Wall St. Rank hold RVNC as of Q3 2021.

  • Charter Oak Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Charter Oak Capital Management sold 500 Revance Therapeutics, Inc. shares in Q3 2021, an estimated $15K.
  • Charter Oak Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2021 and held it in 2 quarters.
  • Charter Oak Capital Management's Revance Therapeutics, Inc. position peaked at $15K in Q2 2021.
  • 158 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2021.

Based on Charter Oak Capital Management's 13F filing for Q3 2021, filed 8 Nov 2021.